トヨハラ ケイコ   TOYOHARA KEIKO
  豊原 啓子
   所属   医学部 医学科(東京女子医科大学病院)
   職種   助教
言語種別 英語
発表タイトル The Effects of Cardiac Resynchronization Therapy Using Transvenous Approach on Clinical Outcome in Patients with Systemic Right Ventricle Failure
会議名 The 79th Annual Scientific Meeting of the Japanese Circulation Society
主催者 Japanese Circulation Society
学会区分 全国規模の学会
発表形式 口頭
講演区分 一般
発表者・共同発表者◎KOGURE Tomohito, SHODA Morio, MANAKA Tetsuyuki, INAI Kei, TOYOHARA Keiko, SHINOHARA Tokuko, NAKANISHI Toshio, HAGIWARA Nobuhisa
発表年月日 2015/04/26
開催地
(都市, 国名)
Osaka, JAPAN
学会抄録 PROGRAM JCS 2015 630
概要 Background: Patients with congenital corrected transposition of the great arteries (ccTGA) frequently develop heart failure. Several previous studies have shown the effects of cardiac resynchronized therapy (CRT). However, most of the cases were implanted by surgical approach because the malposition of the coronary sinus ostium and the variation of the coronary sinus branch cause the technical limitation to implant transvenously. Ames: We aimed to evaluate if transvenous approach is feasible and CRT implanted by the transvenous approach affect on clinical outcome in patients with ccTGA.Methods: Consecutive seven ccTGA patients (age 24 to 72 years) with systemic right ventricle (sRV) failure and who were clinically indicated to implant CRT by the transvenous approach were retrospectively observed for a median of 32 months (range 12 to 108 months). New York Heart Association Functional Class (NYHA), sRV ejection fraction (sRVEF) and cardiothoracic ratio (CTR) were evaluated at baseline and 12 month apart. Results: No major complication was seen during the procedure. After 12 months of CRT implantation, NYHA was improved (3.0±0.5 vs. 1.7±0.4, p<0.01), sRVEF was increased (34±5% vs. 45±4%, p<0.01), and CTR was decreased (55±7% vs.48±6%, p=0.01) significantly. There was no occurrence of death during this study.Conclusion: Transvenous CRT implantation was technically feasible and associated with improvements clinical outcome including NYHA, sRVEF and CTR in patients with ccTGA.